SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Biocon plans to launch drugs in eye-care segment

09 Jul 2010 Evaluate

Biocon Ltd has lined up products in new therapies such as glaucoma/eye-care. It plans to enter the lucrative and growing segment of ophthalmology through synthetic prostaglandins that are used to treat glaucoma, among other problems.

 

Branded formulations, a new range of injectable APIs (basic or active pharma ingredients) and peptides or proteins developed out of complex molecules will join the portfolio through two new divisions, the company said in its latest annual report. This year, it will add Comprehensive Care and Immuno Therapy divisions to the four divisions that currently have 36 brands.

 

With the commercialisation of synthetic prostaglandins used in the treatment of glaucoma, Biocon will make its foray into ophthalmics. The new product range includes synthetic prostaglandins, injectable APIs and peptides, several of which are niche molecules where the technology involved is complex and challenging.

 

With prostaglandin that lowers the fluid pressure in the eye, Biocon would be entering a zone where Allergan, Cipla, Sun Pharma, Bangalore-based Micro Labs and Novartis/Alcon are present. The glaucoma segment, according to an industry source, was around Rs 108 crore last year and is growing at 37 per cent annually.

 

Last year, the Glaucoma Society of India said 12 million people in India were affected and the numbers were rising among the aged. Synthetic prostaglandins have many other uses, such as inducing child birth; treating peptic ulcers; heart defects in new borns; pulmonary hypertension and erectile dysfunction.

crackcrack

Biocon Share Price

360.05 1.85 (0.52%)
20-Apr-2026 11:02 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1677.10
Dr. Reddys Lab 1238.10
Cipla 1238.70
Zydus Lifesciences 942.95
Lupin 2327.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×